ReviewPharmaceuticals (Basel, Switzerland)2020
Current Trends in the Pharmacotherapy of Cataracts.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 64 citations in OpenAlex.
- Assessing the therapeutic effects of DPP4 Inhibitors on TGF-β2-induced Lens Opacity.Experimental eye research · 2026Article
- Comprehensive Modalities for Cataract Management: Preventive, Surgical, and Non-Surgical Approaches Using Conventional and Nanotechnology-Based Therapies.AAPS PharmSciTech · 2026Review
- Cataract Management in the Modern Era: Therapeutic Advances and Unmet Needs.Current pharmaceutical design · 2026Review
- Optical correction in excised cataractous crystalline lenses by using wavefront shaping techniques.Biomedical optics express · 2025Article
- Predictors of time to recovery from cataract surgery among cataract patients at Menelik II Comprehensive Specialized Hospital: a retrospective follow up study.BMC ophthalmology · 2025Article
- Association between serum carotenoid concentrations and risk of major age-related eye diseases among middle-aged and older adults.Frontiers in medicine · 2025Article
- Participation of Lens Proteins and miRs in Traumatic and Inheritance Cataract: A Review on Diagnostic and Therapeutic Approaches for Cataract Management.Current pharmaceutical biotechnology · 2025Review
- Burden of cataracts in developing countries: a trend analysis based on data from China, 1990 to 2021.Frontiers in medicine · 2025Article
- Influence of Cataract Causing Mutations on αA-Crystallin: A Computational Approach.The protein journal · 2024Article
- Quantitative and Rapid In Vivo Imaging of Human Lenticular Fluorescence.Investigative ophthalmology & visual science · 2024Article
- Glutathione Modulates Hydrogen Sulfide Release and the Ocular Hypotensive Action of Diallyl Polysulfide Compounds.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Correction: Heruye et al. Current Trends in the Pharmacotherapy of Cataracts.Pharmaceuticals (Basel, Switzerland) · 2024Article
- GDF-15 Attenuates the Epithelium-Mesenchymal Transition and Alleviates TGFβ2-Induced Lens Opacity.Translational vision science & technology · 2024Article
- The BLV App Arcade: a new curated repository and evaluation rubric for mobile applications supporting blindness and low vision.Disability and rehabilitation. Assistive technology · 2024Article
- Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy.Pharmaceutics · 2024Article
- Neoteric Role of Quercetin in Visual Disorders.Current drug research reviews · 2024Review
- Transcriptome sequencing and microRNA-mRNA regulatory network construction in the lens from a NaBMC ophthalmology · 2023Article
- Vitamin K and the Visual System-A Narrative Review.Nutrients · 2023Review
- Phase-Decorrelation Optical Coherence Tomography Measurement of Cold-Induced Nuclear Cataract.Translational vision science & technology · 2023Article
- Characterization and Bioactive Potential of Carotenoid Lutein fromFoods (Basel, Switzerland) · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cataracts, one of the leading causes of preventable blindness worldwide, refers to lens degradation that is characterized by clouding, with consequent blurry vision. As life expectancies improve, the number of people affected with cataracts is predicted to increase worldwide, especially in low-income nations with limited access to surgery. Although cataract surgery is considered safe, it is associated with some complications such as retinal detachment, warranting a search for cheap, pharmacological alternatives to the management of this ocular disease. The lens is richly endowed with a complex system of non-enzymatic and enzymatic antioxidants which scavenge reactive oxygen species to preserve lens proteins. Depletion and/or failure in this primary antioxidant defense system contributes to the damage observed in lenticular molecules and their repair mechanisms, ultimately causing cataracts. Several attempts have been made to counteract experimentally induced cataract using in vitro, ex vivo, and in vivo techniques. The majority of the anti-cataract compounds tested, including plant extracts and naturally-occurring compounds, lies in their antioxidant and/or free radical scavenging and/or anti-inflammatory propensity. In addition to providing an overview of the pathophysiology of cataracts, this review focuses on the role of various categories of natural and synthetic compounds on experimentally-induced cataracts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.